Figure 8: RvD1 reverses the inhibitory effect of IL-17 on Del-1 expression in vivo.

IL-17 (1 μg) was microinjected into the palatal gingiva with or without RvD1 (1 ng) (a,b) or SB216763 (1 μg) (c,d). In (a,b) certain groups were also microinjected with LY294002 or LY303511 (0.5 μg) as indicated. Mice were euthanized after 24 h and qPCR was used to determine Del-1 mRNA expression levels in dissected gingiva (a,c), whereas ELISA of gingival tissue homogenates was performed to determine Del-1 protein levels (b,d). Different sets of mice were used for qPCR and ELISA to ensure adequate material for analysis. In qPCR, results were normalized to those of GAPDH mRNA and expressed as fold change in transcript levels relative to control mice, the average value of which was taken as 1. In ELISA, Del-1 concentrations were normalized to the total protein concentrations in the tissue homogenates. Data are means±s.d. (n=5 mice per experimental group and n=10 mice per control group; controls were treated with PBS or ethanol and gave similar results, hence the data were pooled). *P<0.01 between indicated groups (ANOVA).